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While the bovine papillomavirus type 1 (BPV-1) E6 induces tumorigenic transformation of murine C127 cells, it does not
bind or promote the degradation of p53. We recently showed the cellular protein ERC-55/E6BP binds BPV-1 E6 as well as
the cancer-related human papillomavirus (HPV) E6 proteins. BPV-1 E6 also binds E6-AP, a ubiquitin ligase necessary for
HPV E6-induced p53 degradation. We previously reported that the transforming activity of a set of BPV-1 E6 mutants
correlated with their E6BP-binding ability. Another function of BPV-1 E6 is stimulation of transcription when targeted to a
promoter, although cellular promoters responsive to BPV-1 E6 have not been identified. To examine whether its transcriptional
function is required for oncogenic activity, or is related to its interactions with E6-AP or E6BP, a series of BPV-1 E6 mutants
were analyzed as fusions to a sequence-specific DNA binding domain for activity in yeast and in mammalian cells. We
show that some transformation defective mutants retained substantial levels of transcriptional activation activity. These
mutants also distinguish transcriptional activation from E6-AP and E6BP binding. These results suggest the transcriptional
activation function of BPV-1 E6 is not sufficient for cell transformation. q 1997 Academic Press
INTRODUCTION ERC-55/E6BP as a cellular binding protein for both high-
risk HPV and BPV-1 E6 proteins (Chen et al., 1995). The
Papillomaviruses (PV) are small DNA viruses that in- transforming activity of a set of previously characterized
fect various epithelial tissues. Some animal PVs, includ- BPV-1 E6 mutants correlated with their ERC-55/E6BP-
ing BPV-1, also induce fibropapillomas. Specific types binding ability, suggesting that this interaction may play
(‘‘high-risk’’) of HPVs infect the anogenital tract and are an important role in BPV-1 E6-mediated transformation.
strongly associated with the development of cervical car- BPV-1 E6 also efficiently binds E6-AP (Chen et al., 1995),
cinoma [for review, see (zur Hausen, 1996)]. BPV-1 the cellular protein through which HPV-16 E6 stimulates
served as the prototype for studies on the transformation ubiquitination and degradation of the tumor suppressor
and molecular biology of the papillomaviruses [for re- protein p53. A candidate cellular target for a potential
view, see (Howley, 1996)]. Most recent investigations BPV-1 E6/E6-AP complex has not been identified.
have analyzed the transforming genes of high risk HPV Several reports demonstrated that E6 from both high-
because of their association with human cancer. risk and low-risk HPVs exhibit transcriptional activation
The BPV-1 and HPV oncogenes manifest their trans- and repression activities on several different promoters
forming potential in varying cell culture-based assays (Gius et al., 1988; Crook et al., 1991; Sedman et al., 1991;
and transgenic models (Howley, 1996). BPV-1 E6, but Desaintes et al., 1992; Etscheid et al., 1994; Morosov et
not the E6 proteins of high-risk genital HPV, efficiently al., 1994; Shirasawa et al., 1994). Some of these effects
induces anchorage-independent growth and focus for- were p53 independent (Etscheid et al., 1994; Akutsu et
mation of C127 cells (Schiller et al., 1984). BPV-1 E6 al., 1996). High-risk HPV E6 were also shown to abrogate
protein is a 137-amino acid protein with two putative zinc the transcriptional activity of p53 (Lechner et al., 1992;
finger motifs that are conserved among all papillomavirus Mietz et al., 1992; Mansur et al., 1995). While HPV E6
E6 proteins. The mechanism of BPV-1 E6-induced cell such as HPV 6 E6 and HPV 16 E6 can activate or repress
transformation is not known. Although BPV-1 E6 has 27% the transcription from several promoters, a BPV-1 E6 re-
amino acid identity to HPV-16 E6, it does not bind or sponsive promoter has not been identified. To evaluate
promote the degradation of p53 (Werness et al., 1990; J. the transcriptional activation properties of BPV-1 E6, it
Chen, unpublished observation). We recently identified was fused to the sequence-specific DNA binding domain
of BPV-1 E2 (E2-R) (Lamberti et al., 1990). This chimeric
E6-E2-R protein activated promoters that incorporated E21 To whom correspondence and reprint requests should be ad-
binding elements in both rodent cells and Saccharo-dressed at Department of Dermatology, New England Medical Center,
myces cerevisiae. In addition, three BPV-1 E6 mutantsBox 166, 750 Washington Street, Boston, MA 02111. Fax: (617) 636-
6190. E-mail: jchen1@opal.tufts.edu. that altered the cysteine motif at the base of each puta-
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tive zinc finger did not stimulate the target promoter. All yeast minimal medium (YMM, His0Ura0) and subse-
quently transferred to galactose/X-gal plates at 307 forthree mutants were shown previously to be transforma-
tion defective in focus formation and anchorage-indepen- 24 hr when color formation was examined.
dent growth assays (Vousden et al., 1989). In contrast,
mutant 212 (isoleucine to threonine substitution at posi- Luciferase assay
tion 41) has wild-type transformation capability and was
NIH 3T3 cells were seeded onto 6-cm dishes at thetransactivation competent. On the basis of this limited
density of 2 1 105/dish one day before transfection. Cellsmutational study, the transformation and transcriptional
were transfected using the Pfx-5 kit (Invitrogen) ac-functions of BPV-1 E6 could not be separated.
cording to the manufacture’s protocol, and cell extractsIn the present study, we employed similar approaches
were collected 40 to 48 hr posttransfection. Of 400 mlto extend our analysis of BPV-1 E6 transcriptional activity.
extract collected from each dish, 20 ml were mixed withBPV-1 E6 mutants were analyzed for transcriptional activ-
40 ml of Luciferase Assay Reagent (Promega) and mea-ity in both yeast and mammalian cells. Our data indicate
sured in a luminometer (MGM Instruments, Inc.).that some transformation defective mutants retained sub-
stantial levels of transcriptional activation activity. These
mutants also distinguish transcriptional activation from Focus formation assay
E6-AP and E6BP binding. These results suggest the tran-
Plasmids encoding BPV-1 E6 or LexA–E6 fusions inscriptional activation function of BPV-1 E6 is not sufficient
the pBabe Puro vector were transfected into the ampho-for cell transformation.
tropic retrovirus packaging cell line PA317 (Miller and
Buttimore, 1986) using calcium phosphate precipitationMATERIALS AND METHODS
(Corsaro and Pearson, 1981). Transfected cells were se-
Plasmids lected for puromycin-resistance. Viruses were collected
and titrated on C127 cells to determine the puromycin-
The yeast plasmids EG202, SH18-34, and JK101 were resistant colony forming units. For focus formation analy-
kindly provided by R. Brent (Gyuris et al., 1993). PEG202 sis, C127 cells grown in Dulbecco’s modified Eagle’s
encodes the Escherichia coli LexA DNA binding protein medium (DMEM) supplemented with 10% fetal bovine
(LexA202, amino acids 1 –202). BPV-1 E6 coding regions serum were infected with retroviruses. Two days after
of wild-type and nine mutants were subcloned as infection, media were switched to DMEM containing 5%
BamHI– SalI fragments from pSP65 or by polymerase fetal bovine serum. Foci formation was examined 2 to 3
chain reaction (PCR) into the BamHI/XhoI sites of plasmid weeks later.
EG202. The yeast reporter plasmid SH18-34 contains
eight LexA binding sites in the promoter region upstream
RESULTSof the lacZ gene. Plasmid JK101 is similar to SH18-34
except that it contains most of the GAL1 upstream acti-
BPV-1 E6 activates transcription when targeted to avating sequence (UAS) upstream of the GAL1 promoter
promoter, although cellular promoters responsive to BPV-TATA sequence, and a LexA binding site lies in between
1 E6 have not been identified. To study BPV-1 E6 tran-the UAS and TATA sequence. Plasmid DBL8 (D. Breiding,
scriptional activity, the E6 coding regions of wild-typeunpublished data) was made by insertion of eight LexA
and nine mutants were subcloned into plasmid EG202,binding sites in the promoter of the luciferase reporter
creating LexA–E6 fusion proteins. The BPV-1 E6 mutantspGL2 (Promega). The HindIII– SalI DNA fragments en-
represent three groups based on their cellular transfor-coding LexA–E6 fusions were subcloned from pEG202
mation phenotypes (e.g., positive, negative, and interme-vector to HindIII/XhoI sites of pcDNA3 (Invitrogen). The
diate). LexA202 does not possess transcriptional activityretrovirus vector pBabe Puro is a Moloney murine leuke-
in yeast or mammalian cells. In contrast to the E6-E2-Rmia virus-based vector containing a puromycin resis-
fusion where E6 is N-terminal to the DNA binding do-tance gene (Morgenstern and Land, 1990). The BamHI–
main, E6 is C-terminal to the LexA DNA binding domain.SalI DNA fragments encoding BPV-1 E6 and the BglII–
This orientation allowed the construction of C-terminalSalI DNA fragments encoding LexA–E6 fusions were
E6 deletion mutant fusions without addition of extrasubcloned to BamHI/SalI sites of pBabe Puro.
amino acid residues, which may lead to ambiguous re-
sults. Mutations were confirmed by DNA sequence and/Yeast assays
or restriction enzyme analyses.
We first tested the transcriptional activity of the LexA–LexA–E6 constructs were transformed together with
reporter plasmids pSH18-34 or JK101 into S. cerevisiae E6 chimera in S. cerevisiae. As expected, yeast colonies
containing the vector LexA202 construct remained whiteEGY48 (Gyuris et al., 1993) by standard LiOAc methods
(Ito et al., 1983). Yeast colonies were grown in selective while those expressing wild-type LexA202-E6 turned blue
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pression assay (Brent and Ptashne, 1984). The repres-
sion assay appears to be more sensitive than immu-
noblot or immunoprecipitation, particularly when the
protein of interest is in low quantity. E6 proteins are
present at very low levels in cells and E6 fusion proteins
expressed in yeast are also difficult to detect (J. Chen,
unpublished observation). Positive results in this repres-
sion assay also imply capacity for nuclear localization
and DNA binding. Accordingly, plasmids encoding mu-
tant BPV-1 E6 as LexA fusion proteins were transformed
into EGY48 along with the reporter plasmid JK101. Plas-
mid JK101 contains the GAL1 UAS followed by lexA oper-
ators upstream of the lacZ coding sequence. Yeast har-
boring JK101 will have significant b-galactosidase activ-
ity when grown on galactose medium. Expression of
LexA fusions that are made, enter the nucleus, and bind
the lexA operator sequences but do not activate tran-
scription will block activation from the UAS, repress b-
galactosidase activity. As shown in Table 1, LexA202
scored positive while the empty vector pEG did not re-
press the target promoter. Mutants 238 and 367 did not
repress the target promoter as efficiently as LexA202.
Although we could not rule out the possibility that these
mutants have intrinsic defects in transcriptional activa-
tion as LexA fusions in yeast, the repression results sug-
FIG. 1. Plasmids encoding wild-type and mutant BPV-1 E6-LexA fu-
gest their negative transcriptional activation phenotypesion proteins were transformed along with reporter plasmid pSH18-34
may be due to lower levels of protein, defective nuclearinto yeast strain EGY48. Colonies formed on Ura0His0glucose YMM
were transferred to Ura0His0galactose-X-gal YMM plate. Photograph localization, or decreased DNA binding. Interestingly,
was taken after 24 hr incubation at 307. both of these mutants are zinc finger mutations. Other
transcription defective mutants were capable of repress-
ing the reporter.
(Fig. 1 and Table 1). Accordingly, the BPV-1 E6 mutants Promoters that are responsive to BPV-1 E6-induced
were examined as LexA fusions. Mutants 212 and 473, transcriptional activation have not been identified. We
which were competent for C127 cell transformation, stim- therefore tested its activity in mammalian cells as LexA
ulated transcription as LexA-E6 fusions. Mutant 228, fusions. The transcriptional activity of BPV-1 E6 was con-
which showed partial transformation activity, also acti- sistently higher in NIH 3T3 cells compared to C127 cells
vated transcription. However, the partially transforming (Lamberti et al., 1990), probably the result of higher trans-
mutant 238 did not activate the reporter gene. Yeast ex- fection efficiency. When NIH 3T3 cells were cotrans-
pressing mutants 359, 367, and 471 remained white. fected with the LexA–E6 (wild-type) and reporter plasmid
These were transformation defective mutants in which pDBL8 that contains eight LexA binding sites in the pro-
the cysteines that form the putative zinc finger bases moter upstream of the luciferase gene, expression of the
were altered. Mutants 359 and 367 have point mutations luciferase gene increased above LexA control in a dose-
while mutant 471 has a deletion. Interestingly, transfor- dependent manner (Fig. 2). LexA–E6 did not significantly
mation defective mutants 438 and 491 activated the activate the parental reporter plasmid pGL2-Promoter
LexA-dependent promoter. Mutant 438 substituted the Vector that does not contain any LexA binding sites, indi-
nonconserved arginine at amino acid 116 with serine. cating the E6 moiety must be localized to the promoter
Mutant 491 has a deletion of the carboxy-terminal four region for this stimulation (data not shown). Similar to
amino acids, none of which appear to be conserved results from transcriptional activation assays in yeast,
among the PV E6 proteins. mutant 212 and 473 stimulated luciferase activity, al-
All mutant E6 proteins analyzed in this study were though the latter activity was weak (Fig. 3 and Table 1).
detectable in mammalian cells (Vousden et al., 1989). It Mutants 359 and 471 did not show significant activity
is possible that the transcriptional activation defective above control levels. Significantly, the transformation de-
phenotype observed for some of these mutants was due fective mutants 367, 438, and 491 were competent in
to instability of the mutant protein in yeast as LexA fu- transcriptional activation in mammalian cells. Both of the
partial transformation competent mutant 228 and 238sions. To evaluate this possibility, we performed a re-
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TABLE 1
Summary of BPV-1 E6 Functions
Amino acid Transactivationa Repression Transactivation E6Bp E6-AP
Name change in yeast ability b in NIH 3T3c Transformation d bindinge bindinge
pEG white blue
LexA202 white white 1
wild type blue N/A f 4.3 /// 100 100
212 Ile41 to Thr blue N/A 5.2 /// 128 90
228 Arg46 to Ser dark blue N/A 2.1 / 14 23
Tyr 47 to His
238 Cys50 to Gly white light blue 1.8 / 12 10
359 Cys90 to Ser white white 1.3 0 0 0
367 Cys93 to His white light blue 2.7 0 0 0
438 Arg116 to Ser blue N/A 2.7 0 0 17
471 Cys127 to Stop white white 1.3 0 0 0
473 Cys128 to Ser dark blue N/A 1.8 /// 105 70
491 Ser134 to Stop blue N/A 4.0 0 0 16
a Colony color.
b Colony color. White color colony indicates the fusion protein is made, localized to the nucleus, and binds LexA binding sites.
c Fold activation over LexA202.
d Transformation data are size of colonies grown on agar rated from / (small) to /// (large); 0, no significant growth (Vousden et al., 1989).
e E6BP and E6-AP binding data are from (Chen et al., 1995). Numbers represent percentage of wild-type BPV-1 E6 association with E6BP.
f Not applicable. Transcriptionally active LexA fusion proteins cannot be examined in this assay.
slightly activated expression of the reporter. The discrep- activity, which is nearly the wild-type level. This result
also indicates that the LexA moiety did not significantlyancy between the transcriptional activities of mutants
238 and 367 from mammalian cells and yeast might be restore transformation activity to this mutant.
explained by their reduced activity in the yeast repres-
sion assay. While these mutant proteins were stable in DISCUSSION
mammalian cells (Vousden et al., 1989), they were defec-
tive in the yeast repression assay. The mechanism of BPV-1 E6-mediated transcriptional
activation is not known. While relieving p53 transcrip-These E6 chimera results may not apply to all potential
BPV-1 E6 responsive promoters, but represent a system tional repression plays a role in high risk HPV E6-medi-
ated transcriptional activation, BPV-1 E6 does not interactto assay the intrinsic transcriptional activity of BPV-1 E6.
Two possible concerns are that the LexA moiety might with p53. The p53 levels in BPV-1 E6-transformed C127
cells were similar to that of parental C127 cells (Schillercompensate for the activity impaired by an E6 mutant,
or it may interfere with E6 function. To address these et al., 1986). Although BPV-1 E6-immortalized primary hu-
man mammary epithelial cells (MEC) demonstrated lowquestions, C127 cell transformation assays using recom-
binant retrovirus which express BPV-1 E6 and the LexA levels and rapid turnover of p53, its half-life and levels
in early passages of MECs expressing BPV-1 E6 wereE6 chimeras were performed. The retrovirus infection
provides a more sensitive way of detecting BPV-1 E6 comparable to normal MECs (Band et al., 1993). This
suggests the reduced level and half-life of p53 in BPV-1transformation as compared with transfection. Using 103
puromycin-resistant colony forming units of wild-type E6 immortalized MECs might be an indirect effect of BPV-
1 E6. Mutants 367, 438, and 491 do not associate withBPV-1 E6 expression retrovirus, we routinely observe
100 foci. Retroviruses expressing LexA–BPV-1 E6 pro- ERC-55/E6BP (Chen et al., 1995, and Table 1) yet still
activated transcription. Furthermore, mutant 367 retainedduced a similar efficiency of transformation of C127 cells,
and therefore the heterologous domain does not interfere substantial transcriptional activity in mammalian cells but
does not bind E6-AP (Table 1). Therefore, transcriptionalwith the E6 focus formation. Using retrovirus infection,
very low level transforming activity (1% of wild-type) was activation by BPV-1 E6 represents an E6-AP and E6BP
independent function of this oncoprotein.observed by mutant 491, although this mutant did not
result in foci using transfection (Vousden et al., 1989). The BPV-1 E6 protein does not contain a glutamine-
rich region or proline repeats found in a variety of tran-The mutant LexA –E6 491 yielded approximately 5% of
the number of foci detected with the wild-type E6 LexA scription factors. It has several negatively charged amino
acids clustered near its center and between the putativehybrid. The transformation efficiency of LexA–E6 491 is
therefore not proportional to its transcriptional activation zinc fingers. This acidic patch is not conserved among
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Dannull et al., 1994; Komatsu and Tozawa, 1994). There
is increasing evidence that zinc finger motifs can mediate
protein–protein interactions. For example, the homodi-
merization of the glucocorticoid receptor and binding of
ZPR1 to the epidermal growth factor receptor appear to
be mediated through their zinc finger domains (Luisi et
al., 1991; Galcheva-Gargova et al., 1996). BPV-1 E6 may
indirectly activate its target promoters by interaction
through its zinc finger domains with cellular transcription
factors or components of the basal transcription appara-
tus. The most relevant example might again be the 13S
adenovirus E1a protein. E1a is not thought to bind directly
to a specific DNA element but rather through interactions
with transcription factors that have sequence-specific
DNA-binding activity. In particular, the activating tran-
scription factor-2 (ATF-2) is thought to localize E1a to the
appropriate promoter where it stimulates formation of
an active transcription complex (Liu and Green, 1990;
Chatton et al., 1993; Liu and Green, 1994; Livingstone et
al., 1995). Alternatively, there may be other mechanisms,
unrelated to the one described here, by which BPV-1 E6
activates transcription.
In conclusion, BPV-1 E6 has two known activities: cell
transformation and transcriptional activation. Likewise, itFIG. 2. Transcriptional activation by BPV-1 E6 in mammalian cells.
has been reported to bind two cellular factors, E6-APNIH 3T3 cells were transfected with 2 mg of luciferase reporter plasmid
and 0 to 4 mg plasmid encoding wild-type LexA-BPV-1 E6 fusion protein and ERC-55/E6BP. In this study we demonstrated that
or 0 to 4 mg of pLexA202B using the Pfx-5 kit. Cell extracts were
assayed for luciferase activity. Fold induction is the ratio between lucif-
erase activity with LexA-BPV-1 E6 and with LexA202 (encoded by
pcDNA3LexA202B) and represents the average of at least three inde-
pendent experiments, each performed in duplicate.
the PV E6 proteins. A similarly small acidic cluster is
present in the 13S adenovirus E1a activating region (Lillie
and Green, 1989). Whether this region contributes to the
activity of BPV-1 E6 in transcription remains to be tested.
Another feature common to adenovirus E1a and E6 is
the putative zinc fingers. BPV-1 E6 has shown to bind
zinc (Barbosa et al., 1989). It is interesting that mutant
238, with a mutation of a cysteine at the base of the first
zinc finger, was able to activate transcription in mamma-
lian cells and to transform C127 cells, albeit with sub-
stantially reduced levels compared to wild type. This cys-
teine residue is followed by another cysteine four amino
acids downstream, which perhaps can inefficiently sub-
stitute for the mutated motif. Mutant 367, with a cysteine
to histidine substitution at the base of the second zinc
finger, was also able to activate transcription in mamma-
lian cells, yet was defective for transformation. Histidine
may substitute cysteine for the coordination of zinc. Zinc
fingers were initially found and described as a motif in
FIG. 3. Transcriptional activation by BPV-1 E6 mutants. NIH 3T3proteins that bind to DNA (Miller et al., 1985; Evans and
cells were transfected with 2 mg of luciferase reporter plasmid and
Hollenberg, 1988). Subsequently, zinc fingers were found 2 mg of plasmids encoding wild-type and mutant BPV-1 E6-LexA
as a structural feature in a number of proteins that inter- fusion proteins and assayed for luciferase activity as described in
the legend to Fig. 2.act with RNA (Gorelick et al., 1988; Joho et al., 1990;
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Evans, M. R., and Hollenberg, S. M. (1988). Zinc finger: gift by associa-BPV-1 E6 mutants that are defective for cell transforma-
tion. Cell 52, 1–3.tion can still activate transcription, implying the BPV-1 E6
Galcheva-Gargova, Z., Konstantinov, K. N., Wu, I.-H., Klier, F. G., Barrett,
transactivation function is not sufficient for induction of T., and Davis, R. J. (1996). Binding of zinc finger protein ZPR1 to the
cellular transformation. Further studies are required to epidermal growth factor receptor. Science 272, 1797–1802.
Gius, D., Grossman, S., Bedell, M. A., and Laimins, L. A. (1988). Induc-explore the mechanisms of both these activities. Our
ible and constitutive enhancer domains in the noncoding region ofresults also indicate BPV-1 E6 transactivation does not
human papillomavirus type 18. J. Virol. 62, 665–672.require its association with either E6-AP or ERC-55/E6BP.
Gorelick, W. R., Henderson, L. E., Hanser, J. P., and Rein, A. (1988). Point
Information obtained from this study should be useful to mutants of Moloney murine leukemia virus that fail to package viral
explore p53-independent functions of PV E6 and to iden- RNA: Evidence for specific recognition by a ‘zinc finger like’ protein
sequence. Proc. Natl. Acad. Sci. USA 85, 8420–8424.tify additional BPV-1 E6 targets.
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